**Claims:**

1. Fixed-dose combination pharmaceutical formulation containing a parent substance, the action of which is dependent on the quantity or the activity of expressed protein variants, enzyme variants, receptor variants or transporter variants, and at least one metabolite thereof.
2. Formulation according to Claim 1, the dosage of which is defined in a genotype- or phenotype-specific manner.
3. Formulation according to either of Claims 1 and 2 comprising tamoxifen and endoxifen.
4. Formulation according to Claim 3 comprising 15–25 mg of tamoxifen and 0.25–5.0 mg of endoxifen.
5. Formulation according to Claim 4 for CYP2D6 IM patients comprising 15–25 mg of tamoxifen and 0.25–2.00 mg of endoxifen.
6. Formulation according to Claim 4 for CYP2D6 PM patients comprising 15–25 mg of tamoxifen and 1.0–5.0 mg of endoxifen.
7. Method for preparing a fixed-dose combination pharmaceutical formulation according to any of Claims 1 to 4, comprising the following steps:
   a) inputting of an organism, of its genotype or phenotype, of a parent substance and at least one metabolite of the parent substance, of an optimal reference steady-state plasma level for the parent substance for a reference genotype or reference phenotype in the case of delivery of the parent substance alone into an input module,
   b) forwarding of the data from a) and b) into a calculation module comprising a substance data module, an organism data module, a genotype data module or phenotype data module, and a physiologically based pharmacokinetic model, wherein the substance data module comprises data concerning the physicochemical and/or biochemical properties of the substance, the organism module comprises data concerning the compartments of the organism, and the genotype data module or phenotype data module comprises genotype- or phenotype-specific data,
   c) automatically selecting parent substance and metabolite-specific data from the substance data module,
   d) automatically selecting organism-specific data from the organism data module on the basis of input a),

e) automatically selecting genotype-specific or phenotype-specific data from the genotype data module or phenotype data module,

f) forwarding of the selected data from a) to e) into the physiologically based pharmacokinetic model,

g) calculating, by means of the physiologically based pharmacokinetic model, an optimized dosage for the parent substance for the reference genotype or reference phenotype in order to attain the inputted optimal reference plasma level for the parent substance from a),

h) calculating the reference steady-state plasma level for the metabolites for the reference genotype or reference phenotype in the case of administration of the dose of parent substance calculated in g),

i) calculating a plasma level of the metabolites that is reduced owing to the genotype or phenotype with respect to the corresponding reference plasma level in the case of administration of the dose of parent substance calculated in g),

j) calculating a metabolite dose and a parent substance dose for the combined attainment of the reference plasma level for the metabolites from h) and of the reference plasma level for the parent substance from a),

k) outputting the metabolite dose and the parent substance dose for the fixed-dose combination pharmaceutical formulation via an output module, and/or forwarding the dose calculated in j) into an automated device for dosing medicaments.

## CLAIMS

1. An invention not claimed in any divisional application.